title: BCL-2 inhibition: stemming the tide of myeloid malignancies.
abstract: Leukemia stem cells (LSCs) are likely to be the source for both therapeutic resistance and relapse in myeloid malignancies. As reported in this issue of Cell Stem Cell, Lagadinou et al. (2013) and Goff et al. (2013) support selective targeting of LSCs by small molecule antagonists of anti-apoptotic BCL-2 family proteins.
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02215, USA.
authors.forename: Leah J
authors.initials: LJ
authors.lastname: Hogdal
authors.forename: Anthony
authors.initials: A
authors.lastname: Letai
mesh_terms: D006801:Humans; D007938:Leukemia / Q000473:pathology*; D015470:Leukemia, Myeloid, Acute / Q000378:metabolism*; D014411:Neoplastic Stem Cells / Q000166:cytology* / Q000187:drug effects*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000037:antagonists & inhibitors* / Q000378:metabolism*
chemical_list: D047428:Protein Kinase Inhibitors; D019253:Proto-Oncogene Proteins c-bcl-2